GW Pharma Cannabinoid-Based Drug approved for Dravet and Lennox Gastaut seizures (Phase 2 in SZ)

"Rounding out GW’s pipeline are GWP42006 (cannabidivarin or CBDV) for epilepsy, which generated disappointing Phase IIa results earlier this year, with clinical trials to start later this year in autism spectrum disorders (ASD) and Rett syndrome; GWP42002/GWP42003 (THC-CBD combination), which completed a Phase II proof-of-concept study in glioblastoma; GWP42003 (CBD) for Neonatal Hypoxic-ischemic Encephalopathy (IV formulation being finalized) and schizophrenia (Phase II proof-of-concept study completed)."

3 Likes

I am looking for sz cbd…!!! Thanks for posting sister…!!!

1 Like

CBD dosages that are used in schizophrenia study’s for a very reasonable price. I already tried their CBD buds with 22%/23% and they’re legit. Will order and trial their high CBD oils in the future.